YTTRIUM Y-90 IBRITUMOMAB TIUXETAN

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Description
Sources: https://www.ema.europa.eu/en/documents/product-information/yttriga-epar-product-information_en.pdf | https://www.ema.europa.eu/en/documents/product-information/ytracis-epar-product-information_en.pdf

YTTRIUM Y-90 (YTRACIS®, YTTRIGA®) is a radioactive form of the chemical element yttrium. It is used for radiolabelling other medicines. An example of its use is the treatment of some type of tumors, where the radiolabelled medicine carries the radioactivity to the site of a tumor to destroy the tumor cells.

Approval Year

Substance Class	Protein Created by `admin` on `Mon Mar 31 18:35:35 GMT 2025` Edited by `admin` on `Mon Mar 31 18:35:35 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1
Sequence Origin	MOUSE
Sequence Type	COMPLETE
Record UNII	QA846JAV5B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

YTTRIUM Y 90 IBRITUMOMAB TIUXETAN

Preferred Name

English

YTTRIUM Y-90 IBRITUMOMAB TIUXETAN

Common Name

English

90Y-IBRITUMOMAB

Common Name

English

90Y IBRITUMOMAB TIUXETAN

Common Name

English

YTTRIUM Y 90 IBRITUMOMAB TIUXETAN [USP IMPURITY]

Common Name

English

YTTRIUM (90Y) IBRITUMOMAB TIUXETAN

Common Name

English

IBRITUMOMAB TIUXETAN Y-90

Common Name

English

IBRITUMOMAB TIUXETAN YTTRIUM Y-90

Common Name

English

Yttrium (90Y) ibritumomab tiuxetan [WHO-DD]

Common Name

English

(90)Y-IBRITUMOMAB TIUXETAN

Common Name

English

Classification Tree Code System Code

WHO-ATC

V10XX02

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

WHO-VATC

QV10XX02

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

NCI_THESAURUS

C1511

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

NCI_THESAURUS

C129819

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

Code System Code Type Description

DRUG BANK

DBSALT001768

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

NCI_THESAURUS

C1812

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

EVMPD

SUB30555

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

ChEMBL

CHEMBL2108667

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

LACTMED

Yttrium 90 Ibritumomab Tiuxetan

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

FDA UNII

QA846JAV5B

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

SMS_ID

100000115279

Created by admin on Mon Mar 31 18:35:35 GMT 2025 , Edited by admin on Mon Mar 31 18:35:35 GMT 2025

PRIMARY

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_295
N	2_295

Related Record Type Details


					TB2Q79LBS0

B-LYMPHOCYTE ANTIGEN CD20

TARGET->LIGAND

Amount:


					TB2Q79LBS0

B-LYMPHOCYTE ANTIGEN CD20

TARGET->RADIOLIGAND

Amount:

Related Record Type Details


					433ME2ATHW

YTTRIUM Y-90 CATION

ACTIVE MOIETY

Amount:


					QA846JAV5B

YTTRIUM Y-90 IBRITUMOMAB TIUXETAN

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
RADIOLABELED MOIETY					YTTRIUM Y-90 CATION	433ME2ATHW
CONJUGATE					TIUXETAN	HKM5WZS29Q

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:ESTIMATED	CHEMICAL
Molecular Formula	CHEMICAL